PortfoliosLab logoPortfoliosLab logo
TEVA vs. INCR
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

TEVA vs. INCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Teva Pharmaceutical Industries Limited (TEVA) and INC Research Holdings Inc (INCR). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, TEVA achieves a 0.87% return, which is significantly lower than INCR's 2.05% return.


TEVA

1D
-3.32%
1M
-7.60%
YTD
0.87%
6M
3.83%
1Y
84.53%
3Y*
61.02%
5Y*
25.48%
10Y*
-4.49%

INCR

1D
-1.09%
1M
9.26%
YTD
2.05%
6M
-35.95%
1Y
-38.09%
3Y*
-24.17%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

TEVA vs. INCR - Yearly Performance Comparison


2026 (YTD)20252024202320222021
TEVA
Teva Pharmaceutical Industries Limited
0.87%41.61%111.11%14.47%13.86%-14.97%
INCR
INC Research Holdings Inc
2.05%-42.77%23.27%-60.92%-49.07%-8.73%

Correlation

The correlation between TEVA and INCR is 0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.05

Correlation (3Y)
Calculated over the trailing 3-year period

0.11

Correlation (All Time)
Calculated using the full available price history since Sep 1, 2021

0.18

The correlation between TEVA and INCR shifts across timeframes, from 0.05 (1 year) to 0.18 (all time), reflecting how their relationship changes across market environments.

Fundamentals

EPS

TEVA:

$1.34

INCR:

-₪1.25

PS Ratio

TEVA:

2.12

INCR:

0.64

Total Revenue (TTM)

TEVA:

$17.35B

INCR:

₪243.12M

Gross Profit (TTM)

TEVA:

$9.03B

INCR:

₪40.61M

EBITDA (TTM)

TEVA:

$3.05B

INCR:

-₪79.49M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

TEVA vs. INCR — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

TEVA
TEVA Risk / Return Rank: 9090
Overall Rank
TEVA Sharpe Ratio Rank: 9090
Sharpe Ratio Rank
TEVA Sortino Ratio Rank: 9292
Sortino Ratio Rank
TEVA Omega Ratio Rank: 9191
Omega Ratio Rank
TEVA Calmar Ratio Rank: 8888
Calmar Ratio Rank
TEVA Martin Ratio Rank: 9090
Martin Ratio Rank

INCR
INCR Risk / Return Rank: 1616
Overall Rank
INCR Sharpe Ratio Rank: 1313
Sharpe Ratio Rank
INCR Sortino Ratio Rank: 1414
Sortino Ratio Rank
INCR Omega Ratio Rank: 1616
Omega Ratio Rank
INCR Calmar Ratio Rank: 1717
Calmar Ratio Rank
INCR Martin Ratio Rank: 1919
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

TEVA vs. INCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Teva Pharmaceutical Industries Limited (TEVA) and INC Research Holdings Inc (INCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


TEVAINCRDifference
Sharpe ratioReturn per unit of total volatility

+2.87

Sortino ratioReturn per unit of downside risk

+4.25

Omega ratioGain probability vs. loss probability

1.42

0.90

+0.52

Calmar ratioReturn relative to maximum drawdown

3.90

-0.66

+4.56

Martin ratioReturn relative to average drawdown

11.35

-1.06

+12.42

TEVA vs. INCR - Sharpe Ratio Comparison

The current TEVA Sharpe Ratio is 2.19, which is higher than the INCR Sharpe Ratio of -0.68. The chart below compares the historical Sharpe Ratios of TEVA and INCR, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

TEVA vs. INCR - Drawdown Comparison

The maximum TEVA drawdown since its inception was -90.89%, roughly equal to the maximum INCR drawdown of -91.57%. Use the drawdown chart below to compare losses from any high point for TEVA and INCR.


Loading charts...

Drawdown Indicators


TEVAINCRDifference

Max Drawdown

Largest peak-to-trough decline

-90.89%

-91.57%

+0.68%

Max Drawdown (1Y)

Largest decline over 1 year

-21.79%

-57.80%

+36.01%

Max Drawdown (3Y)

Largest decline over 3 years

-43.70%

-79.83%

+36.13%

Max Drawdown (5Y)

Largest decline over 5 years

-43.70%

Max Drawdown (10Y)

Largest decline over 10 years

-88.41%

Current Drawdown

Current decline from peak

-53.47%

-89.28%

+35.81%

Average Drawdown

Average peak-to-trough decline

-32.01%

-65.53%

+33.52%

Ulcer Index

Depth and duration of drawdowns from previous peaks

7.47%

35.85%

-28.38%

Volatility

TEVA vs. INCR - Volatility Comparison

The current volatility for Teva Pharmaceutical Industries Limited (TEVA) is 10.98%, while INC Research Holdings Inc (INCR) has a volatility of 28.16%. This indicates that TEVA experiences smaller price fluctuations and is considered to be less risky than INCR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


TEVAINCRDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.98%

28.16%

-17.18%

Volatility (6M)

Calculated over the trailing 6-month period

24.19%

45.79%

-21.60%

Volatility (1Y)

Calculated over the trailing 1-year period

38.87%

55.88%

-17.01%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

42.85%

64.91%

-22.06%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

47.37%

64.91%

-17.54%

Dividends

TEVA vs. INCR - Dividend Comparison

Neither TEVA nor INCR has paid dividends to shareholders.


PositionTTM20252024202320222021202020192018201720162015
INCR
INC Research Holdings Inc
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
TEVA
Teva Pharmaceutical Industries Limited
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%3.88%3.19%1.77%

Financials

TEVA vs. INCR - Financials Comparison

This section allows you to compare key financial metrics between Teva Pharmaceutical Industries Limited and INC Research Holdings Inc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.001.00B2.00B3.00B4.00B5.00B20222023202420252026
3.98B
65.01M
(TEVA) Total Revenue
(INCR) Total Revenue
Please note, different currencies. TEVA values in USD, INCR values in ILS

Frequently Asked Questions


TEVA and INCR have a correlation of 0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

INCR has higher volatility (28.16%) compared to TEVA (10.98%). In terms of maximum drawdown, TEVA dropped -90.89% vs INCR's -91.57%.

TEVA currently has the higher Sharpe Ratio (2.19 vs -0.68), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for TEVA and INCR

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer